Granulocyte-Macrophage Colony-Stimulating Factor
"Granulocyte-Macrophage Colony-Stimulating Factor" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An acidic glycoprotein of MW 23 kDa with internal disulfide bonds. The protein is produced in response to a number of inflammatory mediators by mesenchymal cells present in the hemopoietic environment and at peripheral sites of inflammation. GM-CSF is able to stimulate the production of neutrophilic granulocytes, macrophages, and mixed granulocyte-macrophage colonies from bone marrow cells and can stimulate the formation of eosinophil colonies from fetal liver progenitor cells. GM-CSF can also stimulate some functional activities in mature granulocytes and macrophages.
| Descriptor ID |
D016178
|
| MeSH Number(s) |
D12.644.276.374.410.240.375 D12.776.395.240.300 D12.776.467.374.410.240.375 D23.529.374.410.240.375
|
| Concept/Terms |
Granulocyte-Macrophage Colony-Stimulating Factor- Granulocyte-Macrophage Colony-Stimulating Factor
- Granulocyte Macrophage Colony Stimulating Factor
- CSF-2
- Tumor-Cell Human GM Colony-Stimulating Factor
- Tumor Cell Human GM Colony Stimulating Factor
- GM-CSF
- Histamine-Producing Cell-Stimulating Factor
- Cell-Stimulating Factor, Histamine-Producing
- Histamine Producing Cell Stimulating Factor
- TC-GM-CSF
- Colony-Stimulating Factor, Granulocyte-Macrophage
- Colony Stimulating Factor, Granulocyte Macrophage
- CSF-GM
|
Below are MeSH descriptors whose meaning is more general than "Granulocyte-Macrophage Colony-Stimulating Factor".
Below are MeSH descriptors whose meaning is more specific than "Granulocyte-Macrophage Colony-Stimulating Factor".
This graph shows the total number of publications written about "Granulocyte-Macrophage Colony-Stimulating Factor" by people in this website by year, and whether "Granulocyte-Macrophage Colony-Stimulating Factor" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 1 | 0 | 1 |
| 2004 | 1 | 0 | 1 |
| 2007 | 0 | 1 | 1 |
| 2008 | 1 | 0 | 1 |
| 2010 | 0 | 1 | 1 |
| 2011 | 1 | 0 | 1 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 2 | 1 | 3 |
| 2017 | 9 | 14 | 23 |
| 2018 | 6 | 7 | 13 |
| 2019 | 3 | 2 | 5 |
| 2020 | 7 | 4 | 11 |
| 2021 | 2 | 1 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Granulocyte-Macrophage Colony-Stimulating Factor" by people in Profiles.
-
Comparative transcriptome analyses reveal genes associated with SARS-CoV-2 infection of human lung epithelial cells. Sci Rep. 2021 08 10; 11(1):16212.
-
Granulocyte-macrophage colony-stimulating factor: an immunotarget for sepsis and COVID-19. Cell Mol Immunol. 2021 08; 18(8):2057-2058.
-
Possible inhibition of GM-CSF production by SARS-CoV-2 spike-based vaccines. Mol Med. 2021 05 22; 27(1):49.
-
Monoclonal antibodies capable of binding SARS-CoV-2 spike protein receptor-binding motif specifically prevent GM-CSF induction. J Leukoc Biol. 2022 01; 111(1):261-267.
-
Clonal expansion and activation of tissue-resident memory-like Th17 cells expressing GM-CSF in the lungs of severe COVID-19 patients. Sci Immunol. 2021 02 23; 6(56).
-
Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. Mayo Clin Proc. 2021 03; 96(3):817.
-
In Reply - Clinical Benefit of Lenzilumab in Cases of Coronavirus Disease 2019. Mayo Clin Proc. 2021 03; 96(3):817-818.
-
Granulocyte macrophage colony-stimulating factor has come of age: From a vaccine adjuvant to antiviral immunotherapy. Cytokine Growth Factor Rev. 2021 06; 59:101-110.
-
Immunomodulatory effects of nanocurcumin on Th17 cell responses in mild and severe COVID-19 patients. J Cell Physiol. 2021 07; 236(7):5325-5338.
-
Is G-CSF Dangerous in COVID-19: Why Not Use GM-CSF? Acta Haematol. 2021; 144(3):350-351.